EC
ENTA icon

EcoR1 Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

EcoR1 Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-136,882
Closed -$3.02M – 35
2016
Q2 		$3.02M Sell
136,882
-103,501
-43% -$2.71M 1.19% 23
2016
Q1 		$7.06M Buy
+240,383
New +$6.69M 2.47% 17

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EcoR1 Capital's ENTA Position: Q3 2016 in Review

EcoR1 Capital sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 136,882 shares — an estimated $3.02M sold.

EcoR1 Capital first reported a position in ENTA in Q1 2016 and held it in 2 quarters. The position peaked at $7.06M in Q1 2016. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

  • EcoR1 Capital reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • EcoR1 Capital sold 136,882 Enanta Pharmaceuticals shares in Q3 2016, an estimated $3.02M.
  • EcoR1 Capital first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • EcoR1 Capital's Enanta Pharmaceuticals position peaked at $7.06M in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.